Skip to main content

Biodegradable and biocompatible exceedingly small magnetic iron oxide nanoparticles for T1-weighted magnetic resonance imaging of tumors


Magnetic resonance imaging (MRI) has been widely using in clinical diagnosis, and contrast agents (CAs) can improve the sensitivity MRI. To overcome the problems of commercial Gd chelates-based T1 CAs, commercial magnetic iron oxide nanoparticles (MIONs)-based T2 CAs, and reported exceedingly small MIONs (ES-MIONs)-based T1 CAs, in this study, a facile co-precipitation method was developed to synthesize biodegradable and biocompatible ES-MIONs with excellent water-dispersibility using poly (aspartic acid) (PASP) as a stabilizer for T1-weighted MRI of tumors. After optimization of the synthesis conditions, the final obtained ES-MION9 with 3.7 nm of diameter has a high r1 value (7.0 ± 0.4 mM−1 s−1) and a low r2/r1 ratio (4.9 ± 0.6) at 3.0 T. The ES-MION9 has excellent water dispersibility because of the excessive –COOH from the stabilizer PASP. The pharmacokinetics and biodistribution of ES-MION9 in vivo demonstrate the better tumor targetability and MRI time window of ES-MION9 than commercial Gd chelates. T1-weighted MR images of aqueous solutions, cells and tumor-bearing mice at 3.0 T or 7.0 T demonstrate that our ES-MION9 has a stronger capability of enhancing the MRI contrast comparing with the commercial Gd chelates. The MTT assay, live/dead staining of cells, and H&E-staining indicate the non-toxicity and biosafety of our ES-MION9. Consequently, the biodegradable and biocompatible ES-MION9 with excellent water-dispersibility is an ideal T1-weighted CAs with promising translational possibility to compete with the commercial Gd chelates.


Magnetic resonance imaging (MRI) has been widely using in clinical diagnosis and prognosis observation to distinguish lesions from normal tissues, especially for the diagnosis of tumors, because of its obvious superiorities, including high soft tissue contrast, high spatial resolution, non-invasion and non-radiation [1,2,3,4]. Contrast agents (CAs) play an indispensable role to enhance the sensitivity of MRI. T1-weighted CAs (i.e., positive CAs) can shorten the proton’s longitudinal relaxation time (T1) to produce brighter images, while T2-weighted CAs (i.e., negative CAs) can shorten proton’s transverse relaxation time (T2) to generate darker images [5,6,7,8]. Currently, most clinical T1 CAs are gadolinium (Gd) chelates, including Magnevist (Gd-DTPA), Gadavist (Gd-DO3A-Butriol), Dotarem (Gd-DOTA), Eovist (Gd-EOB-DTPA), Omniscan (Gd-DTPA-BMA), and so on [9,10,11,12]. However, the U.S. food and drug administration (FDA) has warned that the Gd chelates tend to cause nephrogenic system fibrosis and cerebral deposition [13,14,15]. In addition, the T1 imaging capability of the commercial Gd chelates is not strong due to their small longitudinal relaxivity (r1, ~ 4 mM−1 s−1) [16].

In order to overcome the problems of Gd chelates, increasing studies have been focusing on magnetic iron oxide nanoparticles (MIONs) due to their excellent biocompatibility [17,18,19,20]. Actually, MIONs were first used as T2-weighted CAs for examination of human liver in 1994 [21]. Several types of MIONs, such as Supravist, Feridex, and Rsovist, were developed and used as T2 CAs for MRI of human diseases in the 2000s [22]. However, these MION agents are not used in clinic anymore due to the following problems. (1) The MION agents produce darker MR images that are not conducive to the clinician’s diagnosis for diseases [23]. (2) Slow body clearance and long blood circulation lead to long waiting time for patients. (3) The high magnetic moment of MIONs can result in susceptibility artifacts. (4) The long echo time (TE) and repetition time (TR) result in long processing time of clinical MRI examinations. (5) Eovist, a liver-specific T1 contrast agent, was approved in 2008, and used to replace the MIONs-based T2 CAs.

Because there are no ideal products in clinic, MRI CAs have been one of the research hotspots for a long time. The recently emerging ES-MIONs (< 5.0 nm) with high r1 and low transversal relaxivity (r2) can be used as T1 CAs without concerns of nephrotoxicity and cerebral deposition [24,25,26]. Therefore, ES-MIONs can surmount drawbacks of the above-mentioned Gd chelates and MIONs. Kim et al. reported uniform ES-MIONs prepared by a method of thermal decomposition in 2011, which has low r2 value [27]. However, the ES-MIONs synthesized in oil phase are not soluble in water and need further hydrophilic functionalization on their surfaces, which severely limits their clinical applications. To solve this problem, we previously synthesized ES-MIONs with stabilization of poly (acrylic aid) (PAA) in aqueous phase by co-precipitation method [23]. The synthesized ES-MIONs can be easily dispersed in water, and the dispersion can be kept at room temperature for several months without any precipitation. However, the used stabilizer PAA is not biodegradable in human physiological environment.

In this study, a facile co-precipitation method was developed to synthesize biodegradable and biocompatible ES-MIONs (< 5.0 nm) with excellent water-dispersibility for T1-weighted MRI of tumors. As shown in Scheme 1A, biodegradable poly (aspartic acid) (sodium salt, PASP) first react with Fe3+ and Fe2+ to form PASP-Fe chelate, which can further react with ammonia solution producing biodegradable and biocompatible ES-MIONs via co-precipitation. The reaction equation generating Fe3O4 is shown in Scheme 1B. Due to the enrichment of carboxyl groups in the surface, the negatively charged ES-MIONs have excellent water-dispersibility. Because the amide bonds of PASP are biodegradable in human physiological environment, PASP can be used as an excellent candidate as the stabilizer for the synthesis of ES-MIONs. The PASP cannot be replaced with other poly(amino acids) because they are either less water-soluble than PASP, or positively charged. Because the r1 value (7.0 mM−1 s−1) is much higher than that of commercial Gd chelates (~ 4 mM−1 s−1) and the iron is one of the essential elements in the human body, the obtained ES-MIONs are biocompatible and have huge potential to be used as T1 MRI CAs, surpassing the commercial Gd chelates.

Scheme 1
scheme 1

Schematic illustration of synthesis process (A) and reaction equation (B) for the ES-MIONs

Results and discussion

Synthesis and characterization of ES-MIONs

The ES-MIONs were synthesized by a method of co-precipitation, and reaction conditions were optimized to obtain high quality ES-MIONs with high r1 and r2/r1 (Additional file 1: Table S1). PASP was used as a stabilizer for the ES-MIONs preparation, which gives the obtained ES-MIONs excellent water dispersibility. Four concentrations of PASP solutions were used for synthesis of ES-MION1-4. The Fe concentration of ES-MIONs was determined by inductively coupled plasma-optical emission spectrometry (ICP-OES), and the ES-MION2 has the largest Fe recovery of 96.6% (Additional file 1: Table S1). T1 and T2 relaxation rates (3.0 T) versus Fe concentration of ES-MION1-4 are shown in Fig. 1A, B. The r1 and r2 values are obtained from the linear line slopes, which are summarized in Fig. 1E and Additional file 1: Table S1. The ES-MION2 has a r1 value of 1.6 mM−1 s−1 and r2/r1 ratio of 8.8. Though the r1 of ES-MION3, 4 is larger than ES-MION2, the r2/r1 values of ES-MION3, 4 are also much higher than that of ES-MION2, which are not good for T1 imaging. The r2/r1 value of ES-MION1 is lower than that of ES-MION2, but the r1 value is also lower than that of ES-MION2. Therefore, 2.0 mg/mL of PASP solution was considered as the optimal concentration for the synthesis of ES-MIONs.

Fig. 1
figure 1

AD T1 relaxation rate (1/T1) (A, C) or T2 relaxation rate (1/T2) (B, D) plotted versus CFe for ES-MION1-11. E, F The r1 or r2/r1 of the ES-MION1-4 (E) or ES-MION5-8 (F) as a function of CPASP or CNH3·H2O. The magnetic field is 3.0 T

Furthermore, 0.5–8.0% of ammonia solutions were used to synthesize ES-MION5-8, whose T1 and T2 relaxation rates (3.0 T) as a function of Fe concentration are shown in Fig. 1C, D. As shown in Fig. 1F and Additional file 1: Table S1, the r1 and r2/r1 of ES-MION6 are comparable to those of ES-MION5, but much better than ES-MION 7, 8. Therefore, 4.0% of ammonia solution was chosen as the optimal condition.

In addition, based on the optimized conditions for ES-MION6 synthesis, the concentration of PASP and iron precursors (FeCl3 plus FeSO4) were all decreased to synthesize ES-MION9-11. From Fig. 1C, D, F and Additional file 1: Table S1, it can be found that ES-MION9 has a highest r1 value of 7.0 ± 0.4 mM−1 s−1 (3.0 T) and a lowest r2/r1 value of 4.9 ± 0.6 (3.0 T) compared with ES-MION6, 10, 11. According to Eq. (1) [28], the signal intensity of MRI is depended on gradient intensity (M0), echo time (TE), repetition time (TR), flip Angle (α), R2* and R1. The factors of M0, TE, TR, and α could be regulated by MRI scanners, while R2* and R1 depend on contrast agents. The R2* can be considered a valid R2 and is always greater than or equal to R2. It can be concluded that the T1 MRI signal intensity is proportional to r1 value, but inversely proportional to r2/r1 ratio. Thus, the synthesis conditions of ES-MION9 should be optimal to obtain a high T1 MRI capability with a high r1 and low r2/r1.

$${\text{Signal intensity = M}}_{{0}} {\text{sin(}}\alpha {)}\frac{{1 - {\text{e}}^{{ - {\text{R}}_{{1}} \cdot {\text{TR}}}} }}{{1 - {\text{cos(}}\alpha {)} \cdot {\text{e}}^{{ - {\text{R}}_{{1}} \cdot {\text{TR}}}} }}{\text{e}}^{{ - {\text{R}}_{{2}}^{*} \cdot {\text{TE}}}}$$

Besides, Fe recoveries of ES-MION1-11 tested by ICP-OES are all above 85%, indicating high utilization rates of raw materials and low cost for ES-MIONs synthesis, which are beneficial for clinical transformation.

According to previous reports, Fe3O4 nanoparticles with size below 5.0 nm can be used as T1 CAs [24]. Furthermore, Fe3O4 nanoparticles with large particle size are easily taken up by the spleen and liver, which seriously affects tumor images. The images of transmission electron microscopy (TEM, Fig. 2A–K) indicate our ES-MION1-11 have excellent water dispersibility. It is found from the TEM images (Fig. 2A–D) and size distributions (Additional file 1: Fig. S1A–D) measured from TEM images that the concentration of PASP has a large influence on the sizes of ES-MIONs. The sizes of ES-MION1-4 are respectively 2.7, 2.5, 6.0 and 8.0 nm, whose r1 is 1.0, 2.0, 4.7, and 5.4 mM−1 s−1, and the r2/r1 is 1.9, 7.0, 19.0, and 28.3. These results demonstrate that Fe3O4 nanoparticles with size below 5.0 nm have potential as T1 CAs, while those with size larger than 5.0 nm can be only utilized as T2 CAs due to the high r2/r1 ratios. Figure 2E–K and Additional file 1: Fig. S1E–K show that both the concentration of ammonia solution and the whole concentrations of feeding materials have a slight influence on the size of ES-MIONs. The relationships between the particle size and r1 value (or r2/r1 ratio) (Fig. 2L) show that the best particle size is 3.7 nm (ES-MION9).

Fig. 2
figure 2

AK TEM images of ES-MION1-11. L The r1 and r2/r1 of ES-MIONs plotted versus its diameter

Three batches of ES-MION9 were synthesized and the T1/T2 relaxation rates were determined by a 3.0 T (Additional file 1: Fig. S2) and 7.0 T MRI scanner (Additional file 1: Fig. S3), whose similar r1 and r2 data for different batches demonstrate the good repeatability for ES-MION9 synthesis. At 3.0 T, the ES-MION9 has a larger r1 (7.0 ± 0.4 mM−1 s−1) than Gadavist (4.9 ± 0.1 mM−1 s−1), indicating a stronger T1 MRI capability of our ES-MION9.

The related T1-weighted MR images (3.0 T) of ES-MION1-11 are shown in Additional file 1: Figs. S4A, S5A, and S6A. The corresponding SNR and ΔSNR values were calculated according to Eqs. (2) and (3) [29, 30], and shown in Additional file 1: Figs. S4B, S5B, and S6B, which reinforce that the signal intensities of MR images increase with the increase of Fe concentration with a strong concentration gradient dependence, showing good T1-weighted MR capabilities of ES-MION1-11.

$${\text{SNR}} = \frac{{{\text{SI}}_{{{\text{mean}}}} }}{{{\text{SD}}_{{{\text{noise}}}} }}$$
$$\Delta {\text{SNR}} = \frac{{({\text{SNR}}_{{{\text{sample}}}} - {\text{SNR}}_{{{\text{control}}}} )}}{{{\text{SNR}}_{{{\text{control}}}} }} \times 100\%$$

It is obvious that the ΔSNR value of ES-MION9 is the maximum up to 5500% when the Fe concentration of is 1.0 mM (Additional file 1: Fig. S6B), which further demonstrate 3.7 nm is the best diameter of ES-MIONs for T1 MRI.

The T1 images (3.0 T) of ES-MION9 solution at 1.0 mM were further compared with the commercial Gadavist at 1.0 mM of Gd concentration (Fig. 3A). It can be seen from Fig. 3B that the ΔSNR (5400%) of ES-MION9 is higher than that (4600%) of Gadavist (***P < 0.001), which demonstrates the better MR imaging capability of our ES-MION9 (r1 is 7.0 mM−1 s−1, r2/r1 is 4.9, 3.0 T) compared with the Gadavist.

Fig. 3
figure 3

A T1-weighted MR images of ES-MION9 solutions (CFe = 1.0 mM) and commercial Gadavist solutions (CGd = 1.0 mM) compared with pure water (control). Magnetic field = 3.0 T. TE = 8.3 ms, TR = 200 ms. B ΔSNR of the MR images of ES-MION9 and Gadavist solutions, which is measured by the Image J. ***P < 0.001

A 7.0 T of MRI scanner was also used to double confirm the T1-weighted MRI contrast of ES-MION9 solutions at various concentrations compared with pure water (Additional file 1: Fig. S7A). The corresponding ΔSNR values (Additional file 1: Fig. S7B) also show a strong concentration gradient dependence, indicating a strong MRI capability at 7.0 T.

The ES-MION9 HR-TEM image is presented in Additional file 1: Fig. S8A. The lattice planes of 311 and 220 can be confirmed by the 0.51 and 0.301 nm of interplanar distances [31], indicating a crystalline structure of ES-MION9. The characteristic peaks of O and Fe can be found in the EDS (Additional file 1: Fig. S8B), demonstrating the component of iron oxide for ES-MION9 [32]. To further demonstrate the successful synthesis of Fe3O4 nanoparticles, the X-ray photoelectron spectroscopy (XPS) of ES-MION9 is performed in Additional file 1: Fig. S8C. The primary peaks at 723.8 and 710.3 eV correspond to the energy of Fe 2p3/2 and Fe 2p1/2 [33, 34], indicating the Fe3O4 component of our ES-MION9 [23]. Additional file 1: Fig. S8D shows the XRD of ES-MION9. Four characteristic peaks (2θ ≈ 30.0°, 35.2°, 42.8°, and 53.0°) match with the indices [(220), (311), (400), and (511)]. The crystal structure of ES-MION9 matches the pristine of Fe3O4, demonstrating the high crystalline purity of our ES-MION9. The field dependent magnetization curve (Additional file 1: Fig. S8E) indicates the ES-MION9 is superparamagnetic with 16.0 emu/g of saturation magnetization (Ms). All these results indicate that the ES-MION9 we synthesized is superparamagnetic Fe3O4 nanocrystals.

Because the Ms values of ES-MIONs increase with the increasing particle sizes [28], the small Ms value of ES-MION9 indicates its small particle size. In Eq. (4), the r is the magnetic core radius and Ms is the saturation magnetization. According to Eq. (4), both the extremely small particle size (3.7 nm) and small Ms (16.0 emu/g) lead to a very low r2, which results in a very low r2/r1. Therefore, our exceedingly small ES-MION9 can be used as T1 CA.

$$\frac{1}{{{\text{T}}_{2} }} = \frac{{(256\uppi ^{2}\upgamma ^{2} /405){\text{V}}^{*} {\text{M}}_{{\text{S}}}^{2} {\text{r}}^{2} }}{{{\text{D}}(1 + {\text{L}}/{\text{r}})}}$$

The high r1 value of ES-MION9 is mainly due to the following two reasons: (1) ES-MION9 has a small particle size (3.7 nm), which gives ES-MION9 a larger specific surface area. In accordance with the mechanism of inner-sphere, larger specific surface area means there are more naked iron on ES-MION9 surfaces, which can fully interacts with hydrogen protons in H2O molecules, resulting in a high r1 value. (2) There are excessive carboxyl groups on ES-MION9 surfaces, and these carboxyl groups are derived from PASP, which greatly improves the water dispersion of ES-MION9. This leads to more H2O in the inner sphere that can interact with the naked iron on the ES-MION9 surface, which causes a large number of bound H2O (q) and mole fraction of H2O coordinated to Fe (Pm) in Eq. (5) [16]. The large q and Pm result in a large r1 value for ES-MION9.

$$\frac{1}{{{\text{T}}_{1} }} = \frac{{{\text{q P}}_{{\text{m}}} }}{{{\text{T}}_{{1{\text{m}}}} + \tau_{{\text{M}}} }}$$

The T1/T2 relaxation rate (1/T1 or 1/T2) is plotted versus concentration for contrast agents, and the r1 and r2 values are calculated from the slopes of the corresponding fitting lines. T1 CAs increase signal intensity of T1 images by shortening the longitudinal relaxation time (T1) of protons, which leads to high r1 values. The Fe3O4 nanoparticles with size below 5.0 nm have low Ms values causing low r2 values according to Eq. (4). Both high r1 and low r2 result in low r2/r1. Therefore, the 3.7 nm of ES-MION9 (< 5.0 nm) could be utilized for T1 MRI [35, 36].

The hydrodynamic size (dh) of ES-MION9 is 13.7 nm (Additional file 1: Fig. S9A), which is larger than renal filtration threshold (~ 8 nm). The slightly larger hydrodynamic diameter prolongs blood circulation time overcoming the limited MRI time window problem of commercial Gd chelates. The zeta potential of ES-MION9 was measured to be − 55.0 mV (Additional file 1: Fig. S9B), which is due to the presence of excessive carboxyl groups on the surface. Charge plays a key role in the behavior of intravenously injected nanoparticles and pharmacokinetics. For example, nanoparticles agglomerate under charge-mediated nonspecific binding to serum proteins. Sufficient negative charges can avoid the agglomeration of ES-MION9 while avoiding uptake of the nanoparticles by normal cells during blood circulation, resulting in more accumulated ES-MION9 in tumors. Additional file 1: Fig. S9C shows that the hydrodynamic diameter of ES-MION9 do not change significantly during storage in water, 10.0% FBS and 0.9% NaCl solution for 1 week, demonstrating the great stability of ES-MION9.

Additional file 1: Fig. S10 shows UV–vis absorption spectra for ES-MION1-11, which are similar with that of reported ES-MIONs stabilized with other polymers [23]. Additional file 1: Fig. S11 shows the FT-IR of PASP and ES-MIONN9. The stretching vibration peak of –CH2– at 1400.6 cm−1 can be seen from the FT-IR of PASP and ES-MION9, indicating the existence of PASP on the surface of ES-MION9 [37]. In addition, the stretching vibration peak of Fe–O at 604.5 cm−1 can be seen from the FT-IR of ES-MION9, but not in the FT-IR of PASP, indicating the existence of iron in ES-MION9. These results prove the successful synthesis of Fe3O4 [38]. Additional file 1: Fig. S12 presents the curves of thermogravimetric analysis (TGA) and differential thermogravimetry (DTG) for ES-MION9. As the temperature increases, the mass of ES-MION9 continues to decrease, and becomes stable at 37.8% of remaining mass. This is similar to 40.1% of Fe3O4 loading content for ES-MION9 measured by ICP. This result further demonstrates the existence of PASP on the ES-MION9 surface.

Cellular uptake, cytotoxicity assay and T1-weighted imaging of cells

To evaluate the biosafety of ES-MION9, its cytotoxicity was examined by thiazolyl blue tetrazolium bromide (MTT) assay on MCF-7 cells (Human breast cancer cells) and 4T1 cells (Mouse breast cancer cells). Figure 4A, B shows that when the Fe concentration of ES-MION9 reaches 0.8 mM, the cell viability of MCF-7 cells and 4T1 cells was higher than 95.0%. This result indicates that ES-MION9 is almost not cytotoxic due to its biocompatible components (i.e., Fe3O4 and PASP). Although Gd3+ can cause nephrogenic systemic fibrosis and can be deposited in the human brain and body [39], Fig. 4A, B shows that the Gadavist is also non-toxic at the Gd concentration of 0.8 mM. That’s because Gd3+ leads to long-term toxicity, which cannot be revealed in the short-term MTT assay.

Fig. 4
figure 4

A, B Cytotoxicity of ES-MION9, commercial Gadavist or Magnevist on 4T1 cells or MCF-7 cells. Mean ± SD, n = 4. C LSCM images of 4T1 cells treated with ES-MION9@R6G for 2.0 h. The cytoskeleton is green due to the phalloidin-FITC staining, and the nucleus is blue due to the DAPI staining

To further demonstrate the non-cytotoxicity of ES-MION9, live/dead cytotoxicity analysis was used to evaluate the toxicity of ES-MION9 to 4T1 cells and MCF-7 cells (Additional file 1: Figs. S13, S14). The PBS treated cells were used as a control. Green dots represent live cells and red dots represent dead cells. Obviously, almost no dead cells are found for ES-MION9-treated 4T1 cells and MCF-7 cells, showing good biosafety of ES-MION9. That’s because the main component aspartic acid (ASP) is one of the 20 essential amino acids and iron is one of the essential elements in the human body.

Figure 4C shows the LSCM images of 4T1 cells treated with ES-MION9@R6G. The red signal represents R6G@ES-MION9. After 2 h of co-incubation with 4T1 cells, lots of ES-MION9 nanoparticles were found inside the cells (Fig. 4C). The uptake of ES-MION9 by 4T1 cells was further investigated by flow cytometry. After 2 h of co-incubation with 4T1 cells, the fluorescence intensity (Additional file 1: Fig. S15A, B) of R6G-labeled ES-MION9 was almost two orders of magnitude higher than that of the control group with a statistical P value smaller than 0.001, indicating that ES-MION9 is easily taken up by 4T1 cells. The results of flow cytometry are consistent with the LSCM results. In addition, the T1-weighted MR images (7.0 T) (Additional file 1: Fig. S16) show that ES-MION9-treated tumor cells have much stronger MRI signals compared to the control groups, and the MR signal also increases with the increase of incubation time from 1.0 to 2.0 h. These results demonstrate the excellent MR imaging capability of our ES-MION9 at the cellular level.

In vivo MR imaging

MRI can be used for soft tissue imaging, especially for tumor diagnosis. MR contrast agents can improve the signal-to-noise ratio and sensitivity of MRI. We tested the imaging ability of ES-MION9 in 4T1 tumor-bearing mice. 4T1 cells were seeded subcutaneously into BALB/c mice to build 4T1 tumor models. The commercial Gadavist and our ES-MION9 were i.v. injected into the 4T1 tumor-bearing mice for MR imaging (Fig. 5A, B). It can be seen from the MR images that after the administration of Gadavist or ES-MION9, the tumor becomes brighter than that of control (pre-injection), and reaches the brightest at 30 min or 3.0 h post-injection, respectively. MR images of different slices were obtained at each time point, and the brightest one of different slices at each time point was selected to characterize the MR imaging capabilities. Because the contrast difference between tumor and normal tissue is usually hard to be identified by the naked eyes, the signal changes in tumors at various time points after the administration of contrast agents are quantified using ΔSNR as shown in Fig. 5C, D, which is calculated according to the Eq. (6):

$$\Delta {\text{SNR}} = \frac{{({\text{SNR}}_{{{\text{post}}}} - {\text{SNR}}_{{{\text{pre}}}} )}}{{{\text{SNR}}_{{{\text{pre}}}} }} \times 100\%$$
Fig. 5
figure 5

A, B: T1-weighted MR images of 4T1 tumor-bearing BALB/c mice with or without i.v. injection of Gadavist at 5.0 mg/kg of Gd dosage (A), or ES-MION9 at 5.0 mg/kg Fe dosage (B) under 7.0 T of magnetic field. C, D ΔSNR of the MR images for Gadavist (C), or ES-MION9 (D). E, F Blood clearance profile (E) and in vivo biodistribution of Fe level (F) in the 4T1 tumor-bearing BALB/c mice after i.v. injection of ES-MION9. Fe dosage is 5.0 mg/kg. **P < 0.01

The ΔSNR value is up to 93.4% at 3.0 h after administration of ES-MION9 (Fig. 5D), which is significantly larger than that of the tumor at 30 min post-injection of Gadavist (57.2%, Fig. 5C). The above results demonstrate that our ES-MION9 can be utilized as a stronger MRI CAs compared with the clinically used Gd chelates.

Pharmacokinetics, biodistribution and biosafety evaluation in vivo

To verify that our ES-MION9 is more biocompatible and safer than Gadavist, the pharmacokinetics, biodistribution and biosafety were evaluated in vivo. Figure 5E shows that the blood half-life of ES-MION9 is about 2.3 h due to the small nanoparticle size (3.7 nm). The best time window for MRI in clinic is close to the half-life (10–15 min) of commercial Gd chelates, which is a little bit tight for MRI after administration of the Gd chelates [40]. The slightly longer half-life of our ES-MION9 overcomes the limited MRI time window problem of commercial Gd chelates.

To evaluate the biodistribution of ES-MION9 in vivo, the Fe contents in the heart, liver, spleen, lung, kidney and tumor of mice were measured at 0 h pre-injection and 12.0 h post-injection of ES-MION9, and the differences are shown in Fig. 5F. It is found the ES-MION9 accumulation inside tumors is very high compared with other normal tissues because of the enhanced permeability and retention (EPR) effect, which is the key reason for the highly enhanced MRI signal of tumors after ES-MION9 injection.

Additional file 1: Fig. S17 shows the representative optical microscopic pictures of the H&E-stained main organs from the normal mice without tumors (control), or that with i.v. injection of ES-MION9 (CFe = 5.0 mg/kg). Compared with controls, ES-MION9-treated mice showed no obvious pathological abnormalities in major organs (heart, liver, spleen, lung, and kidney), indicating that our ES-MION9 does not lead to systemic toxicity.


In summary, in order to surmount the problems of commercial Gd chelates-based T1 CAs, commercial MIONs-based T2 CAs, and reported ES-MIONs-based T1 CAs, a facile method based on co-precipitation was developed to synthesize biodegradable and biocompatible ES-MIONs with excellent water-dispersibility for T1 MRI of tumors using PASP as the stabilizer. After optimization of the synthesis conditions, the final obtained ES-MION9 with a diameter of 3.7 nm has a high r1 (7.0 ± 0.4 mM−1 s−1) and a low r2/r1 (4.9 ± 0.6) at 3.0 T. The ES-MION9 has excellent water dispersibility due to the excessive carboxyl groups from PASP. The physical properties of ES-MION9 were further characterized by TEM, XRD, EDS, XPS, UV–vis, FT-IR, TGA, and magnetization curve. LSCM images and flow cytometry results prove the cellular uptake of ES-MION9 by endocytosis. The pharmacokinetics, and biodistribution of ES-MION9 in vivo demonstrate the better tumor targetability and MRI time window of ES-MION9 than commercial Gd chelates. T1-weighted MR images of aqueous solutions, cells and tumor-bearing mice at 3.0 T or 7.0 T demonstrate that our ES-MION9 has a stronger MRI capability than the commercial Gd chelates. The MTT assay, live/dead staining of cells, and H&E-staining indicate the non-toxicity and biosafety of our ES-MION9. Consequently, the biodegradable and biocompatible ES-MION9 with excellent water-dispersibility is an ideal T1-weighted CAs with promising translational possibility to compete with the commercial Gd chelates.

Materials and methods

Synthesis of ES-MIONs

In order to eliminate O2, 20.0 mL and 0.5–4.0 mg mL−1 of PASP (Mw = 7000) solution was first bubbled using N2 for 60 min. After that, the solution was heated to 100 °C under reflux. A Fe solution (0.4 mL, 125.0–500.0 mM FeCl3 + 62.5–250.0 mM FeSO4) was then rapidly charged to the above-mentioned PASP solution. Subsequently, NH3.H2O (6.0 mL, 0.5–8.0%) was added under magnetic stirring. After 1.0 h, the reaction was stopped by cooling off. Finally, the synthesized ES-MIONs were purified via dialysis (Mw cut-off 8–14 kDa) in pure water for purification. An ICP-OES (iCAP PRO, Thermo Fisher Scientific, US) was used to determine the CFe of the ES-MIONs.

Synthesis of R6G@ES-MION9

At room temperature, 70.0 µL of Rhodamine 6G (100.0 μM) was added into 4.0 mL of ES-MION9 (CFe = 2.8 mM), and the mixture was magnetically stirred for 24.0 h. The prepared R6G@ES-MION9 solution was then centrifugally ultra-filtrated (Millipore, Mw cutoff 10 kDa) and washed utilizing ultrapure water for purification. Finally, the obtained R6G@ES-MION9 was resolved in ultrapure water (4.0 mL) and kept in 4.0 °C of refrigerator.

Availability of data and materials

All data associated with this study are present in the paper and/or the additional file.


  1. Poon C, Gallo J, Joo J, Chang T, Banobre-Lopez M, Chung EJ. Hybrid, metal oxide-peptide amphiphile micelles for molecular magnetic resonance imaging of atherosclerosis. J Nanobiotechnol. 2018;16:1–11.

    Article  Google Scholar 

  2. Kawano T, Murata M, Kang JH, Piao JS, Narahara S, Hyodo F, Hamano N, Guo J, Oguri S, Ohuchida K. Ultrasensitive MRI detection of spontaneous pancreatic tumors with nanocage-based targeted contrast agent. Biomaterials. 2018;152:37–46.

    Article  CAS  Google Scholar 

  3. Li X, Feng Q, Jiang X. Microfluidic synthesis of Gd-based nanoparticles for fast and ultralong MRI signals in the solid tumor. Adv Healthc Mater. 2019;8:1900672.

    Article  CAS  Google Scholar 

  4. Zheng D, Yang K, Nie ZV. Engineering heterogeneity of precision nanoparticles for biomedical delivery and therapy. View. 2021;2:20200067.

    Article  Google Scholar 

  5. Sitharaman B, Wilson LJ. Gadonanotubes as new high-performance MRI contrast agents. Int J Nanomed. 2006;1:291.

    CAS  Google Scholar 

  6. Wang Q, Liang Z, Li F, Lee J, Low LE, Ling D. Dynamically switchable magnetic resonance imaging contrast agents. Exploration. 2021;9:20210009.

    Article  Google Scholar 

  7. Han Y, Zhou X, Qian Y, Hu H, Zhou Z, Liu X, Tang J, Shen Y. Hypoxia-targeting dendritic MRI contrast agent based on internally hydroxy dendrimer for tumor imaging. Biomaterials. 2019;213:119195.

    Article  CAS  Google Scholar 

  8. Zhang M, Xing L, Ke H, He Y-J, Cui P-F, Zhu Y, Jiang G, Qiao J-B, Lu N, Chen H. MnO2-based nanoplatform serves as drug vehicle and MRI contrast agent for cancer theranostics. ACS Appl Mater Interfaces. 2017;9:11337–44.

    Article  CAS  Google Scholar 

  9. Wang F, Bae K, Huang Z, Xue J. Two-photon graphene quantum dot modified Gd2O3 nanocomposites as a dual-mode MRI contrast agent and cell labelling agent. Nanoscale Horiz. 2018;10:5642–9.

    Article  CAS  Google Scholar 

  10. Haylor J, Dencausse A, Vickers M, Nutter F, Jestin G, Slater D, Idee JM, Morcos S. Nephrogenic gadolinium biodistribution and skin cellularity following a single injection of Omniscan in the rat. Invest Radiol. 2010;45:507–12.

    Article  Google Scholar 

  11. Fidler J, Hough D. Hepatocyte-specific magnetic resonance Imaging contrast agents. Hepatology. 2011;53:678–82.

    Article  Google Scholar 

  12. Ananta JS, Godin B, Sethi R, Moriggi L, Liu X, Serda RE, Krishnamurthy R, Muthupillai R, Bolskar RD, Helm L. Geometrical confinement of gadolinium-based contrast agents in nanoporous particles enhances T1 contrast. Nat Nanotechnol. 2010;5:815–21.

    Article  CAS  Google Scholar 

  13. Xue X, Bo R, Qu H, Jia B, Xiao W, Yuan Y, Vapniarsky N, Lindstrom A, Wu H, Zhang D. A nephrotoxicity-free, iron-based contrast agent for magnetic resonance imaging of tumors. Biomaterials. 2020;257:120234.

    Article  CAS  Google Scholar 

  14. Mendichovszky IA, Marks SD, Simcock CM, Olsen OE. Gadolinium and nephrogenic systemic fibrosis: time to tighten practice. Pediatr Radiol. 2008;38:489–96.

    Article  Google Scholar 

  15. Ledneva E, Karie S, Launay-Vacher V, Janus N, Deray G. Renal safety of gadolinium-based contrast media in patients with chronic renal insufficiency. Radiology. 2009;250:618.

    Article  Google Scholar 

  16. Shen Z, Fan W, Yang Z, Liu Y, Bregadze VI, Mandal SK, Yung BC, Lin L, Liu T, Tang W. Exceedingly small gadolinium oxide nanoparticles with remarkable relaxivities for magnetic resonance imaging of tumors. Small. 2019;15:1903422.

    Article  CAS  Google Scholar 

  17. Shu G, Chen M, Song J, Xu X, Lu C, Du Y, Xu M, Zhao Z, Zhu M, Fan K. Sialic acid-engineered mesoporous polydopamine nanoparticles loaded with SPIO and Fe3+ as a novel theranostic agent for T1/T2 dual-mode MRI-guided combined chemo-photothermal treatment of hepatic cancer. Bioact Mater. 2021;6:1423–35.

    Article  CAS  Google Scholar 

  18. Zhao S, Yu X, Qian Y, Chen W, Shen J. Multifunctional magnetic iron oxide nanoparticles: an advanced platform for cancer theranostics. Theranostics. 2020;10:6278.

    Article  CAS  Google Scholar 

  19. Na HB, Song IC, Hyeon T. Inorganic nanoparticles for MRI contrast agents. Adv Mater. 2009;21:2133–48.

    Article  CAS  Google Scholar 

  20. Wang Z, Qiao R, Tang N, Lu Z, Wang H, Zhang Z, Xue X, Huang Z, Zhang S, Zhang G. Active targeting theranostic iron oxide nanoparticles for MRI and magnetic resonance-guided focused ultrasound ablation of lung cancer. Biomaterials. 2017;127:25–35.

    Article  CAS  Google Scholar 

  21. Cai Z, Wu C, Yang L, Wang D, Ai H. Assembly-controlled magnetic nanoparticle clusters as MRI contrast agents. ACS Biomater Sci Eng. 2020;6:2533–42.

    Article  CAS  Google Scholar 

  22. Reimer P, Balzer T. Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications. Eur Radiol. 2003;13:1266–76.

    Article  Google Scholar 

  23. Shen Z, Chen T, Ma X, Ren W, Zhou Z, Zhu G, Zhang A, Liu Y, Song J, Li Z. Multifunctional theranostic nanoparticles based on exceedingly small magnetic iron oxide nanoparticles for T1-weighted magnetic resonance imaging and chemotherapy. ACS Nano. 2017;11:10992–1004.

    Article  CAS  Google Scholar 

  24. Shen Z, Wu A, Chen X. Iron oxide nanoparticle based contrast agents for magnetic resonance imaging. Mol Pharm. 2017;14:1352–64.

    Article  CAS  Google Scholar 

  25. Xiang C, Zhong X, Yang W, Majeed MI, Wang J, Yu J, Hu J, Xu Z, Tan B, Zhang B, Yan W. Fe3O4 nanoparticles functionalized with polymer ligand for T1-weighted MRI in vitro and in vivo. Polymers. 2019;11:882.

    Article  CAS  Google Scholar 

  26. Liu Y, Yang Z, Huang X, Yu G, Wang S, Zhou Z, Shen Z, Fan W, Liu Y, Davisson M. Glutathione-responsive self-assembled magnetic gold nanowreath for enhanced tumor imaging and imaging-guided photothermal therapy. ACS Nano. 2018;12:8129–37.

    Article  CAS  Google Scholar 

  27. Kim BH, Lee N, Kim H, An K, Park YI, Choi Y, Shin K, Lee Y, Kwon SG, Na HB. Large-scale synthesis of uniform and extremely small-sized iron oxide nanoparticles for high-resolution T1 magnetic resonance imaging contrast agents. J Am Chem Soc. 2011;133:12624–31.

    Article  CAS  Google Scholar 

  28. Shin TH, Kim PK, Kang S, Cheong J, Kim S, Lim Y, Shin W, Jung J-Y, Lah JD, Choi BW. High-resolution T1 MRI via renally clearable dextran nanoparticles with an iron oxide shell. Nat Biomed Eng. 2021;5:252–63.

    Article  CAS  Google Scholar 

  29. Wei Z, Jiang Z, Pan C, Xia J, Xu K, Xue T, Yuan B, Akakuru OU, Zhu C, Zhang G. Ten-gram-scale facile synthesis of organogadolinium complex nanoparticles for tumor diagnosis. Small. 2020;16:1906870.

    Article  CAS  Google Scholar 

  30. Cai Y, Wang Y, Zhang T, Pan Y. Gadolinium-labeled ferritin nanoparticles as T1 contrast agents for magnetic resonance imaging of tumors. ACS Appl Nano Mater. 2020;3:8771–83.

    Article  CAS  Google Scholar 

  31. Liang H, Wu X, Zhao G, Feng K, Ni K, Sun X. Renal clearable ultrasmall single-crystal Fe nanoparticles for highly selective and effective ferroptosis therapy and immunotherapy. J Am Chem Soc. 2021;143:15812–23.

    Article  CAS  Google Scholar 

  32. Shen Z, Song J, Zhou Z, Yung BC, Aronova MA, Li Y, Dai Y, Fan W, Liu Y, Li Z. Dotted core-shell nanoparticles for T1-weighted MRI of tumors. Adv Mater. 2018;30:03163.

    Google Scholar 

  33. Chen Y, Song B, Tang X, Lu L, Xue J. Ultrasmall Fe3O4 nanoparticle/MoS2 nanosheet composites with superior performances for lithium ion batteries. Small. 2014;10:1536–43.

    Article  CAS  Google Scholar 

  34. Zhang J, Wang K, Xu Q, Zhou Y, Cheng F, Guo S. Beyond yolk-shell nanoparticles. Fe3O4@Fe3C core@shell nanoparticles as yolks and carbon nanospindles as shells for efficient lithium ion storage. ACS Nano. 2015;9:3369–76.

    Article  CAS  Google Scholar 

  35. Lu Y, Xu YJ, Zhang GB, Ling D, Wang MQ, Zhou Y, Wu YD, Wu T, Hackett MJ, Hyo KB. Iron oxide nanoclusters for T1 magnetic resonance imaging of non-human primates. Nat Biomed Eng. 2017;1:637–43.

    Article  CAS  Google Scholar 

  36. Ling D, Park W, Park SJ, Lu Y, Kim KS, Hackett MJ, Kim BH, Yim H, Jeon YS, Na K. Multifunctional tumor pH-sensitive self-assembled nanoparticles for bimodal imaging and treatment of resistant heterogeneous tumors. J Am Chem Soc. 2014;136:5647–55.

    Article  CAS  Google Scholar 

  37. Ahsan HM, Zhang X, Liu Y, Wang Y, Li Y, Li B, Wang J, Liu S. Stable cellular foams and oil powders derived from methylated microcrystalline cellulose stabilized pickering emulsions. Food Hydrocoll. 2020;104:105742.

    Article  CAS  Google Scholar 

  38. Xu S, Wang J, Wei Y, Zhao H, Tao T, Wang H, Wang Z, Du J, Wang H, Qian J. Interfaces. In situ one-pot synthesis of Fe2O3@BSA core-shell nanoparticles as enhanced T1-weighted magnetic resonance imagine contrast agents. ACS Appl Mater Interfaces. 2020;12:56701–11.

    Article  CAS  Google Scholar 

  39. Attari H, Cao Y, Elmholdt TR, Zhao Y, Prince MR. A systematic review of 639 patients with biopsy-confirmed nephrogenic systemic fibrosis. Radiology. 2019;292:376–86.

    Article  Google Scholar 

  40. Huang CH, Nwe K, Al Zaki A, Brechbiel MW, Tsourkas A. Biodegradable polydisulfide dendrimer nanoclusters as MRI contrast agents. ACS Nano. 2012;6:9416–24.

    Article  CAS  Google Scholar 

Download references


Not applicable.


This work was supported in part by the Guangzhou Key Research and Development Program of China (202103000094), Guangdong Provincial Natural Science Foundation of China (2021A1515010605), Zhejiang Provincial Natural Science Foundation of China (LR19E030001), and National Natural Science Foundation of China (51761145021).

Author information

Authors and Affiliations



XQ, YX, and ZS conceptualized the study; XL, HZ, ZL, JF, YL, and LH carried out the experiments, and analyzed data; XL and HZ performed statistical analyses, prepared the figures, and wrote the manuscript draft. XQ, YX, and ZS participated in manuscript reviewing. ZS secured the funding. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Xiaozhong Qiu, Yikai Xu or Zheyu Shen.

Ethics declarations

Ethics approval and consent to participate

All animal procedures were performed in accordance with the Guidelines for Care and Use of Laboratory Animals of Southern Medical University and approved by the Animal Ethics Committee of Southern Medical University.

Consent for publication

All authors agree to publish this manuscript.

Competing interests

The authors declare no competing financial interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1. 

The online version contains supplementary material available at

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lu, X., Zhou, H., Liang, Z. et al. Biodegradable and biocompatible exceedingly small magnetic iron oxide nanoparticles for T1-weighted magnetic resonance imaging of tumors. J Nanobiotechnol 20, 350 (2022).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: